Synaptosome-associated protein 25 (SNAP-25)

Synaptosome-associated protein 25 (SNAP-25) is a core component of the SNARE complex, essential for the calcium-triggered exocytosis of neurotransmitters (UniProt: P60880). It is primarily localized to the presynaptic plasma membrane where it mediates the docking and fusion of synaptic vesicles (PubMed: 23454378). SNAP-25 exists in two isoforms, SNAP-25a and SNAP-25b, which are differentially expressed during development and in different brain regions (NIH: Gene ID 6616). Dysfunction or abnormal expression of SNAP-25 has been implicated in the pathogenesis of neuropsychiatric disorders such as ADHD and schizophrenia, as well as neurodegenerative diseases like Alzheimer’s, where it serves as a biomarker for synaptic loss (PubMed: 31213136). The protein is a major pharmacological target for Botulinum neurotoxin type A (BoNT/A), which cleaves SNAP-25 at its C-terminus, thereby preventing the formation of the SNARE complex and blocking acetylcholine release at the neuromuscular junction (StatPearls: NBK557387). This mechanism is utilized therapeutically to treat conditions like cervical dystonia, chronic migraine, and muscle spasticity (DrugBank: DB00063).

Other names

Synaptosomal-associated 25 kDa proteinSuperproteinSUPSNAPRIC-4RIC4SNAP25

Targeting drugs, specifically botulinum neurotoxins, act as zinc-dependent endopeptidases that proteolytically cleave SNAP-25 at specific sites near the C-terminus. This cleavage prevents the assembly of the functional SNARE (Soluble NSF Attachment Protein Receptor) complex, which is required for the docking and fusion of neurotransmitter-containing vesicles with the presynaptic membrane, thereby inhibiting the release of acetylcholine and other neurotransmitters.